Welcome to our dedicated page for Tela Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TELA Bio, Inc. (NASDAQ: TELA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. TELA Bio is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, and its filings offer detailed information on financial performance, capital structure, governance, and material agreements that affect TELA stock.
Investors can review current reports on Form 8-K, where TELA Bio reports material events such as entry into significant credit agreements, registered direct offerings of common stock and pre-funded warrants, and changes in directors and compensatory arrangements. For example, the company has filed 8-Ks describing a senior secured term loan facility with Perceptive Credit Holdings V, LP, the terms of associated warrants to purchase common stock, and the termination of a prior credit and security agreement. Other 8-Ks furnish press releases announcing quarterly financial results and updated investor presentations.
Through its periodic reports (10-K and 10-Q, accessible via EDGAR and summarized on this page), users can analyze TELA Bio’s revenue, gross profit, operating expenses, and net loss, as well as balance sheet items such as cash, long-term debt, and stockholders’ equity. These filings also contain risk factor discussions covering macroeconomic conditions, surgical procedure volumes, competition, product development and manufacturing issues, and reimbursement considerations.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major changes in revenue trends, liquidity, debt covenants, and equity offerings. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks, and related exhibits appear promptly, while insider and equity-related disclosures such as warrant issuances and director equity awards can be examined alongside the underlying text.
For anyone researching TELA Bio’s regulatory history, financing arrangements, and board-level changes, this filings page offers a structured view of the company’s official disclosures with AI assistance to interpret complex legal and financial language.
TELA Bio is registering up to 2,000,000 shares of common stock for resale by Perceptive Credit Holdings V, LP, issuable upon exercise of a warrant connected to a November 2025 credit agreement. These shares may be sold from time to time on Nasdaq or in private transactions at market or negotiated prices, with the selling stockholder paying its own selling commissions while TELA covers registration expenses. TELA will not receive proceeds from any resale of these shares, but could receive cash if the warrant is exercised, which it currently plans to use for general corporate purposes such as sales and marketing, research and development, working capital and capital spending.
TELA Bio is a commercial-stage medical technology company focused on soft-tissue reconstruction, led by its OviTex hernia repair and OviTex PRS plastic and reconstructive surgery product portfolios. The company cites an estimated U.S. addressable market of about $1.8 billion for OviTex and $800 million for OviTex PRS. A key risk highlighted is that future sales of these registered shares by the selling stockholder, or the perception that such sales may occur, could put downward pressure on TELA’s stock price.
TELA Bio, Inc. reported an insider share purchase by major holders connected to EW Healthcare Partners. On 11/17/2025, these reporting persons acquired 3,604,000 shares of TELA Bio common stock in the company’s underwritten registered direct offering at a price of $1.11 per share. After this transaction, they beneficially own a total of 7,714,709 shares, split between EW Healthcare Partners Fund 2, L.P. and EW Healthcare Partners Fund 2-A, L.P. The filing notes that control over voting and investment decisions for these shares is held through the EW Healthcare general partner structure and its managers, who each disclaim ownership beyond their pecuniary interests.
TELA Bio entered a senior secured term loan with Perceptive for up to $70.0 million. An initial $60.0 million will fund on November 14, 2025, with an additional $10.0 million delayed draw available subject to conditions. The facility matures on November 14, 2030, bears interest at 7.85% plus the greater of the Reference Rate or 4.25% (minimum 12.10% per annum), has no scheduled amortization, and includes prepayment premiums of 2%–10%. Obligations are secured by a first‑lien on substantially all assets.
As consideration, TELA will issue warrants to purchase up to 2,000,000 shares at $1.11 on closing and up to 333,333 shares at $1.11 if the delayed draw is funded; the warrants expire on November 14, 2035 and permit cashless exercise and resale registration rights. A post‑closing condition requires evidence by November 17, 2025 of at least $8,500,000 in gross proceeds from a registered direct offering.
Separately, TELA launched an underwritten registered direct offering of 4,189,000 shares at $1.11 and 7,523,000 pre‑funded warrants at $1.1099, for expected net proceeds of about $11.9 million. Pre‑funded warrants are immediately exercisable at $0.0001 with a 9.99% (or 4.99%) beneficial ownership cap. The prior MidCap facility was terminated and its lien released.
TELA Bio, Inc. filed its quarterly report, showing higher sales and a narrower loss. Revenue for Q3 2025 reached $20.7 million, up 9% from $19.0 million a year ago, with gross margin steady at 68%. The company reported a net loss of $8.6 million for the quarter, an improvement from a $10.4 million loss in Q3 2024. For the first nine months of 2025, revenue was $59.4 million versus $51.7 million in 2024, while net loss was $29.8 million compared to $28.6 million, which included a prior-year gain on a product line sale.
Cash and cash equivalents were $29.7 million as of September 30, 2025, down from $52.7 million at year-end, driven by operating cash outflows of $23.3 million year‑to‑date. Long-term debt was $41.5 million. Subsequent to quarter‑end, TELA closed a new credit facility of up to $70.0 million with Perceptive, including an initial $60.0 million draw used in part to repay its MidCap loan; the facility bears interest at 7.85% plus the greater of one‑month Term SOFR or 4.25% and is interest‑only until November 14, 2030. The company also entered an underwriting agreement for an underwritten registered direct offering of 4,189,000 shares at $1.11 per share and pre‑funded warrants for 7,523,000 shares at $1.1099 per warrant, for expected gross proceeds of approximately $13.0 million, subject to customary closing conditions.
TELA Bio, Inc. launched a registered direct offering of common stock and, in lieu of shares for certain buyers, pre-funded warrants. Each pre-funded warrant is exercisable for one share at an exercise price of $0.0001 and will be sold at the per‑share offering price minus $0.0001. This prospectus also covers the shares issuable upon exercise of the pre-funded warrants. The company’s common stock trades on Nasdaq as “TELA,” and the last reported price was $1.14 per share on November 12, 2025.
Separately, TELA entered into a senior secured term loan facility with Perceptive for up to $70.0 million, including an initial $60.0 million funding and a $10.0 million delayed draw, maturing November 14, 2030. Interest equals a 7.85% margin plus the greater of the Reference Rate or 4.25%, with prepayment premiums of 2% to 10%. As consideration, TELA will issue Perceptive warrants for up to 2,000,000 shares, and an additional 333,333 shares tied to the delayed draw, expiring November 14, 2035. A post‑closing condition requires at least $8,500,000 in gross proceeds from this registered direct offering. Preliminary Q3 2025 results show revenue of $20.7 million versus $19.0 million a year ago, gross margin of approximately 68%, and cash and equivalents of $29.7 million.
TELA Bio, Inc. furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025 and updated its corporate slide deck.
The press release is furnished as Exhibit 99.1 and the investor presentation as Exhibit 99.2, each dated November 13, 2025. The materials are furnished, not filed, and are not subject to Section 18 liability, and are incorporated by reference only if specifically referenced in a future filing.
TELA Bio (TELA) reported a director equity grant. On 10/31/2025, the reporting person acquired 11,925 shares of common stock at $0 (restricted stock units), bringing beneficial ownership of common stock to 11,925 shares, held directly.
The filing also shows a stock option for 17,550 shares at an exercise price of $1.23, expiring on 10/31/2035. The RSUs vest in three equal annual installments beginning 10/31/2026, and the option vests in 36 equal monthly installments starting 10/31/2025, in each case subject to continued service.
TELA Bio reported an insider update: a director filed a Form 3 initial statement of beneficial ownership.
The filing states no securities are beneficially owned as of the event date of 10/31/2025. The form was filed by one reporting person under Section 16.
TELA Bio expanded its Board of Directors from six to seven members and appointed William Plovanic as a Class I director, with his term expiring at the 2026 Annual Meeting of Stockholders. The Board determined he is an independent director under Nasdaq rules.
Plovanic, 56, brings experience as Managing Director of Healthcare Equity Research at Canaccord Genuity and prior leadership roles at Obalon Therapeutics. Upon appointment, he received an initial equity award consisting of an option to purchase 17,550 shares vesting in 36 equal monthly installments and 11,925 RSUs vesting in three equal annual installments, granted under the company’s 2019 Equity Incentive Plan. He will receive a $45,000 annual cash retainer for Board service. Beginning at the 2026 Annual Meeting, his annual equity awards will include options for 11,700 shares and 7,950 RSUs, each vesting on the earlier of one year from grant, the next annual meeting, or a change in control, subject to continued service.
Reporting person: Betty Jo Rocchio, a director at TELA Bio, Inc. (TELA), reported securities awards received on 10/09/2025 and the filing was signed on 10/10/2025.
The report shows 11,925 restricted stock units (RSUs) granted with zero purchase price; these RSUs vest in three equal annual installments beginning on 10/09/2026, subject to continued service. The filing also reports a stock option to buy 17,550 shares with an exercise price of $1.48, granted on 10/09/2025, vesting monthly over 36 months and expiring on 10/09/2035.